Turn Therapeutics announces peer-reviewed publication supporting GX-03's activity in IL-36 inflammatory model

Turn Therapeutics Inc.

Study in murine dermatitis model showed mean IGA score of 1.44 vs 3.00 for untreated controls (p=0.0003) after 7 days of GX-03.
No treatment-related adverse effects observed; IL-36 expression confirmed following Staphylococcus aureus exposure.
Publication in Journal of Dermatological Treatment; first in planned series on GX-03's scientific rationale.
GX-03 is in Phase 2 for moderate-to-severe atopic dermatitis; topline results expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.